<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Congenital nasolacrimal duct obstruction (dacryostenosis) and dacryocystocele</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Congenital nasolacrimal duct obstruction (dacryostenosis) and dacryocystocele</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Congenital nasolacrimal duct obstruction (dacryostenosis) and dacryocystocele</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Evelyn A Paysse, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David K Coats, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Scott E Olitsky, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 09, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Congenital nasolacrimal duct (NLD) obstruction (dacryostenosis) occurs in approximately 6 percent of newborns and is the most common cause of persistent tearing and ocular discharge in infants and young children. Most cases resolve spontaneously. Congenital dacryocystocele (or nasolacrimal duct cyst) occurs less commonly but is associated with potentially serious complications and, hence, requires timely referral to an ophthalmologist.</p><p>The clinical features, evaluation, and management of congenital NLD obstruction and dacryocystocele will be discussed below. The anatomy of the lacrimal system, other causes of persistent tearing, and the approach to the child with persistent tearing are discussed separately. (See  <a class="medical medical_review" href="/d/html/6262.html" rel="external">"Approach to the child with persistent tearing"</a>.)</p><p class="headingAnchor" id="H717054611"><span class="h1">ANATOMY AND PATHOPHYSIOLOGY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Normal tear production and drainage</strong> – Tears are produced by the main and accessory lacrimal glands. They drain medially into the puncta in the upper and lower eyelids, flowing through the canaliculi to the lacrimal sac and through the nasolacrimal duct (NLD) into the nose (<a class="graphic graphic_figure graphicRef53429" href="/d/graphic/53429.html" rel="external">figure 1</a>). The NLD has a proximal valve (valve of Rosenmuller) and a distal valve (valve of Hasner) (<a class="graphic graphic_figure graphicRef53429" href="/d/graphic/53429.html" rel="external">figure 1</a>), which are common sites of obstruction. (See  <a class="medical medical_review" href="/d/html/6262.html" rel="external">"Approach to the child with persistent tearing", section on 'Anatomy and physiology of the lacrimal system'</a>.)</p><p></p><p class="bulletIndent1">During embryonic development, the nasolacrimal apparatus appears in the third to fifth week and gradually forms a cord of epithelium that extends from the eyelids to the nose. Canalization of the cord begins at the punctum in the eyelid during the third month of intrauterine life and extends distally toward the nose. Canalization is usually complete by birth.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Common sites of obstruction</strong> – Obstruction at different locations in the nasolacrimal system causes different manifestations:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Congenital NLD obstruction</strong> – The most common cause of congenital NLD obstruction is incomplete canalization at the distal end (ie, closest to the nose), leaving an imperforate membrane at the valve of Hasner (<a class="graphic graphic_figure graphicRef53429" href="/d/graphic/53429.html" rel="external">figure 1</a>); however, NLD obstruction can also occur at other sites [<a href="#rid1">1</a>]. (See <a class="local">'Nasolacrimal duct obstruction'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Congenital dacryocystocele</strong> – Congenital dacryocystoceles (also known as dacryoceles, amniotoceles, or NLD cysts) are produced when both the proximal and distal portions of the nasolacrimal system are obstructed. Like simple congenital NLD obstruction, the distal obstruction is usually at the level of the membrane of Hasner. The proximal obstruction typically occurs in the common canaliculus or at the valve of Rosenmuller (<a class="graphic graphic_figure graphicRef53429" href="/d/graphic/53429.html" rel="external">figure 1</a>). The proximal obstruction is a one-way valve that permits tears to enter but not to reflux out of the canaliculi of the lacrimal drainage system. This results in distention of the lacrimal sac and duct, which appears as a bluish bulge below the medial canthus (<a class="graphic graphic_picture graphicRef62273" href="/d/graphic/62273.html" rel="external">picture 1</a>). (See <a class="local">'Dacryocystocele'</a> below.)</p><p></p><p class="headingAnchor" id="H772423929"><span class="h1">NASOLACRIMAL DUCT OBSTRUCTION</span></p><p class="headingAnchor" id="H3"><span class="h2">Epidemiology</span><span class="headingEndMark"> — </span>Congenital nasolacrimal duct (NLD) obstruction occurs in approximately 6 percent of newborns, usually as an isolated finding, and is the most common cause of persistent tearing and ocular discharge in infants and young children [<a href="#rid1">1-3</a>]. In one study, 20 percent of healthy infants demonstrated evidence of defective lacrimal drainage at some point during the first year of life [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H265432334"><span class="h2">Natural history</span><span class="headingEndMark"> — </span>Approximately 80 to 90 percent of infants with congenital NLD obstruction have spontaneous resolution by the age of 6 to 10 months [<a href="#rid4">4-6</a>].</p><p>Among infants with persistent symptoms at age 9 to 10 months, approximately one-half have resolution within the next six months [<a href="#rid6">6-8</a>]. NLD obstructions that persist beyond the age of 12 months are unlikely to resolve spontaneously [<a href="#rid4">4</a>].</p><p>In a large retrospective study of nearly 2000 infants with congenital NLD obstruction, approximately 85 percent had spontaneous resolution and 15 percent underwent treatment [<a href="#rid6">6</a>]. The rate of spontaneous resolution decreased with age and plateaued after age nine months:</p><p class="bulletIndent1"><span class="glyph">●</span>47 percent of cases resolved by age three months</p><p class="bulletIndent1"><span class="glyph">●</span>66 percent resolved by age six months</p><p class="bulletIndent1"><span class="glyph">●</span>76 percent resolved by age nine months</p><p class="bulletIndent1"><span class="glyph">●</span>78 percent resolved by age 12 months</p><p></p><p>Spontaneous resolution occurred sooner in patients with unilateral compared with bilateral NLD obstruction and in male infants compared with females [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>Infants with congenital NLD obstruction present with a history of chronic or intermittent tearing and debris on the eyelashes ("mattering") (<a class="graphic graphic_picture graphicRef52654" href="/d/graphic/52654.html" rel="external">picture 2</a>).</p><p>Parents may note overflow of tears when the child is in an environment that stimulates a greater production of tears (eg, wind or cold) or when outflow of tears is reduced from swelling of nasal mucosa during an upper respiratory infection. Such "stress epiphora" may occur frequently enough that it becomes bothersome.</p><p>On physical examination, there is usually an increase in the size of the tear meniscus and there may be debris on the eyelashes ("mattering") (<a class="graphic graphic_picture graphicRef52654" href="/d/graphic/52654.html" rel="external">picture 2</a>). Palpation of the lacrimal sac may cause reflux of tears and/or mucoid discharge onto the eye through the puncta. Conjunctival erythema is not typical, although irritation from overflow tearing and chronic rubbing of the eyes may cause mild redness of the lower eyelid (<a class="graphic graphic_picture graphicRef62518" href="/d/graphic/62518.html" rel="external">picture 3</a>).</p><p class="headingAnchor" id="H772425520"><span class="h2">Evaluation and diagnosis</span><span class="headingEndMark"> — </span>The diagnosis is typically made by history and physical examination alone. If symptoms are intermittent and there are no signs of abnormal tearing or mattering at the time of examination, the dye disappearance test (described below) can be performed to confirm the diagnosis.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assess for concerning symptoms</strong> – When evaluating an infant with abnormal tearing, the clinician should assess for other symptoms or findings that may raise concern for a more serious eye condition (see <a class="local">'Differential diagnosis'</a> below and  <a class="medical medical_review" href="/d/html/6262.html" rel="external">"Approach to the child with persistent tearing"</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Purulent discharge, erythema, or swelling, which may suggest infection (eg, ophthalmia neonatorum (<a class="graphic graphic_picture graphicRef66751" href="/d/graphic/66751.html" rel="external">picture 4</a>) or acute dacryocystitis (<a class="graphic graphic_picture graphicRef65777" href="/d/graphic/65777.html" rel="external">picture 5</a>)) (see <a class="local">'Infection'</a> below and  <a class="medical medical_review" href="/d/html/4983.html" rel="external">"Gonococcal infection in the newborn", section on 'Ophthalmia neonatorum'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bluish swelling of the skin overlying the lacrimal sac, suggesting a dacryocystocele (<a class="graphic graphic_picture graphicRef62273" href="/d/graphic/62273.html" rel="external">picture 1</a>) (see <a class="local">'Dacryocystocele'</a> below)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Photophobia, corneal clouding, and/or large or asymmetric corneal diameters, suggesting glaucoma (see  <a class="medical medical_review" href="/d/html/6273.html" rel="external">"Primary infantile glaucoma"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dye disappearance test</strong> – If the diagnosis is uncertain, the dye disappearance test can be performed to help confirm the diagnosis. The test is performed as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Place a drop of topical anesthetic into the eye (or use a <a class="drug drug_pediatric" data-topicid="105145" href="/d/drug information/105145.html" rel="external">fluorescein</a> drop that contains a topical anesthetic).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Place a drop of fluorescein-stained <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> in the inferior cul-de-sac of each of the patient's eyes.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Wipe away the excess tears from the eyelids.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Observe the patient for five minutes. The eyes should not be rubbed; the tears that drain to the cheeks should not be wiped.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>After five minutes, inspect the eyes.</p><p></p><p class="bulletIndent1">All of the <a class="drug drug_pediatric" data-topicid="105145" href="/d/drug information/105145.html" rel="external">fluorescein</a> should drain into the nose within five minutes if the lacrimal drainage system has no obstruction. The test is normal if most of the dye is gone within five minutes and abnormal if a large amount of the dye persists or has drained over the lower eyelid and down the cheek.</p><p></p><p class="headingAnchor" id="H772425527"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>Causes of abnormal tearing in infants and children are summarized in the table (<a class="graphic graphic_table graphicRef63904" href="/d/graphic/63904.html" rel="external">table 1</a>) and discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/6262.html" rel="external">"Approach to the child with persistent tearing", section on 'Etiology of persistent tearing'</a>.):</p><p>The <strong>absence</strong> of the following signs and symptoms distinguishes congenital NLD obstruction from other causes of persistent tearing:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eye redness and/or discomfort</strong> – Eye redness and discomfort are prominent features of conjunctivitis (infectious, allergic, or irritant induced), uveitis, and corneal abrasion or foreign body. Patients with NLD obstruction have little or no eye redness. (See  <a class="medical medical_review" href="/d/html/6907.html" rel="external">"Conjunctivitis"</a> and  <a class="medical medical_review" href="/d/html/6897.html" rel="external">"Corneal abrasions and corneal foreign bodies: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Photophobia</strong> – Photophobia commonly occurs with corneal abrasions, uveitis, and infantile glaucoma. (See  <a class="medical medical_review" href="/d/html/6262.html" rel="external">"Approach to the child with persistent tearing", section on 'Uveitis'</a> and  <a class="medical medical_review" href="/d/html/6273.html" rel="external">"Primary infantile glaucoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Signs of infection</strong> – In newborns, purulent eye discharge raises concern for ophthalmia neonatorum, which is usually caused by infection with <em>Neisseria</em> <em>gonorrhoeae</em> or <em>Chlamydia</em> <em>trachomatis</em> (or both organisms together). While infants with NLD obstruction can sometimes have purulent eye discharge due to bacterial overgrowth in the stagnant tear pool, the presence of copious purulent discharge in a newborn within the first two to three weeks after birth should prompt evaluation for ophthalmia neonatorum, particularly if other signs of infection are present (eg, redness and swelling of the eyelids) (<a class="graphic graphic_picture graphicRef66751" href="/d/graphic/66751.html" rel="external">picture 4</a>). (See  <a class="medical medical_review" href="/d/html/4983.html" rel="external">"Gonococcal infection in the newborn", section on 'Ophthalmia neonatorum'</a> and  <a class="medical medical_review" href="/d/html/4993.html" rel="external">"Chlamydia trachomatis infections in the newborn", section on 'Conjunctivitis'</a>.)</p><p></p><p class="headingAnchor" id="H347896"><span class="h2">Indications for referral</span><span class="headingEndMark"> — </span>Most infants with congenital NLD obstruction can be diagnosed and managed by the primary care practitioner. Referral to an ophthalmologist is warranted if any of the following are present:</p><p class="bulletIndent1"><span class="glyph">●</span>Uncertain diagnosis, particularly if there is concern for infantile glaucoma (suggested by abnormal tearing associated with photophobia, blepharospasm, corneal clouding, and/or large or asymmetric corneal diameters). (See <a class="local">'Differential diagnosis'</a> above and  <a class="medical medical_review" href="/d/html/6273.html" rel="external">"Primary infantile glaucoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms of NLD obstruction that persist beyond the age of six to seven months. (See <a class="local">'Natural history'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Signs and symptoms of acute dacryocystitis (erythema, swelling, warmth, tenderness of the lacrimal sac, and/or purulent discharge) (<a class="graphic graphic_picture graphicRef65777" href="/d/graphic/65777.html" rel="external">picture 5</a>). (See <a class="local">'Infection'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Signs of anisometropia or amblyopia, detected by the Bruckner simultaneous red reflex test (<a class="graphic graphic_figure graphicRef66431" href="/d/graphic/66431.html" rel="external">figure 2</a>). In one study, 10 percent of children with unilateral congenital NLD obstruction were found to have anisometropia (with or without amblyopia) [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/d/html/6260.html" rel="external">"Refractive errors in children"</a> and  <a class="medical medical_review" href="/d/html/6255.html" rel="external">"Amblyopia in children: Classification, screening, and evaluation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical findings suggesting dacryocystocele (a bluish swelling of the skin overlying the lacrimal sac and superior displacement of the medial canthal tendon) (<a class="graphic graphic_picture graphicRef62273" href="/d/graphic/62273.html" rel="external">picture 1</a>). (See <a class="local">'Dacryocystocele'</a> below.)</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Management</span></p><p class="headingAnchor" id="H1569224345"><span class="h3">General approach</span><span class="headingEndMark"> — </span>Management of congenital NLD obstruction is summarized in the algorithm (<a class="graphic graphic_algorithm graphicRef101554" href="/d/graphic/101554.html" rel="external">algorithm 1</a>) and described in the following sections:</p><p class="bulletIndent1"><span class="glyph">●</span>For most patients, management is nonsurgical and consists of lacrimal sac massage (often referred to as "Crigler" massage) and observation. (See <a class="local">'Initial management'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For infants with NLD obstruction that persists beyond age 6 to 10 months, lacrimal duct probing can be performed. (See <a class="local">'Persistent nasolacrimal duct obstruction beyond age 6 to 7 months'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For older children, who usually require general anesthesia for NLD intervention, NLD intubation is often performed rather than simple probing. (See <a class="local">'Persistent nasolacrimal duct obstruction beyond age 6 to 7 months'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>More invasive surgical interventions (which include balloon dacryoplasty, dacryocystorhinostomy, and conjunctivodacryocystorhinostomy) are reserved for patients with treatment failure after less invasive interventions. (See <a class="local">'Treatment failure'</a> below.)</p><p></p><p class="headingAnchor" id="H10"><span class="h3">Initial management</span></p><p class="headingAnchor" id="H3880341751"><span class="h4">Lacrimal sac massage</span><span class="headingEndMark"> — </span>External digital massage of the lacrimal sac is the first-line treatment for NLD obstruction [<a href="#rid10">10</a>]. Massage is believed to relieve the obstruction by increasing the hydrostatic pressure enough to force open the obstructed distal membrane. The term "massage" may not adequately convey the amount of pressure required, and some practitioners use the term "lacrimal sac compression" to more effectively communicate what the maneuver consists of [<a href="#rid11">11</a>].</p><p>Lacrimal sac massage is performed by applying moderate pressure over the lacrimal sac in a downward direction for two to three seconds (<a class="graphic graphic_figure graphicRef101426" href="/d/graphic/101426.html" rel="external">figure 3</a>). It is important to demonstrate the technique to caregivers to ensure that it is performed correctly (ie, so they understand how much pressure to apply). Caregivers are instructed to perform this maneuver two to three times per day until symptoms resolve. Caregivers should be instructed to keep their fingernails trimmed and to wash their hands before and after performing lacrimal sac massage.</p><p class="headingAnchor" id="H884150042"><span class="h4">Treatment of bacterial overgrowth</span><span class="headingEndMark"> — </span>Mucopurulent eye discharge occurs commonly in infants with NLD obstruction and, in the absence of other signs of infection, suggests bacterial overgrowth in the stagnant tear pool of the lacrimal sac. The organisms most commonly isolated include <em>Streptococcus</em> <em>pneumoniae</em>, <em>Haemophilus</em> <em>influenzae</em>, <em>Pseudomonas</em> <em>aeruginosa</em>, and <em>Streptococcus</em> <em>viridans</em> [<a href="#rid12">12</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mucopurulent discharge WITHOUT other signs of infection</strong> – Mucopurulent discharge without other signs of infection suggests bacterial overgrowth rather than infection. This often can be managed with nonpharmacological measures such as eye washes and nasolacrimal sac compression to reduce the mucus and bacteria. If these measures are not successful, treatment with topical antibiotics is a reasonable option. We typically use topical antibiotics only when the discharge is copious and present throughout the day. In addition, if a tear duct procedure is planned and the infants has mucopurulent drainage, topical antibiotic therapy should be provided before the procedure.</p><p></p><p class="bulletIndent1">Commonly used agents include <a class="drug drug_pediatric" data-topicid="12716" href="/d/drug information/12716.html" rel="external">polymyxin B</a>/<a class="drug drug_pediatric" data-topicid="12865" href="/d/drug information/12865.html" rel="external">trimethoprim</a> or <a class="drug drug_pediatric" data-topicid="12845" href="/d/drug information/12845.html" rel="external">tobramycin</a> sulfate 0.3%, one drop up to four times per day. Other appropriate agents include topical <a class="drug drug_pediatric" data-topicid="13332" href="/d/drug information/13332.html" rel="external">gentamicin</a>, <a class="drug drug_pediatric" data-topicid="13276" href="/d/drug information/13276.html" rel="external">erythromycin</a>, <a class="drug drug_pediatric" data-topicid="12813" href="/d/drug information/12813.html" rel="external">sulfacetamide</a>, and if all these others are not effective, a fluoroquinolone can be considered (eg, <a class="drug drug_pediatric" data-topicid="13157" href="/d/drug information/13157.html" rel="external">ciprofloxacin</a>, <a class="drug drug_pediatric" data-topicid="12962" href="/d/drug information/12962.html" rel="external">ofloxacin</a>, <a class="drug drug_general" data-topicid="9710" href="/d/drug information/9710.html" rel="external">norfloxacin</a>, or <a class="drug drug_pediatric" data-topicid="114796" href="/d/drug information/114796.html" rel="external">moxifloxacin</a>). To avoid chemical irritation, the duration of treatment should be short (three to five days).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Purulent discharge WITH other signs of infection</strong> – Purulent eye discharge associated with other signs of infection such as erythema and/or swelling suggests acute dacryocystitis (<a class="graphic graphic_picture graphicRef65777" href="/d/graphic/65777.html" rel="external">picture 5</a>), which requires systemic antibiotic therapy. This a rare complication of isolated congenital NLD obstruction. It occurs more commonly with dacryocystoceles. Management is discussed below. (See <a class="local">'Management of acute dacryocystitis'</a> below.)</p><p></p><p class="headingAnchor" id="H11"><span class="h3">Persistent nasolacrimal duct obstruction beyond age 6 to 7 months</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Referral</strong> – Infants with symptoms of NLD obstruction that have not resolved by age six to seven months should be referred to an ophthalmologist for further evaluation and management. Evaluation should include comprehensive eye examination, including cycloplegic refraction to look for anisometropia, which can occur in approximately 10 percent of patients with congenital NLD obstruction [<a href="#rid9">9,13</a>]. (See  <a class="medical medical_review" href="/d/html/6260.html" rel="external">"Refractive errors in children", section on 'Anisometropia'</a> and  <a class="medical medical_review" href="/d/html/6255.html" rel="external">"Amblyopia in children: Classification, screening, and evaluation", section on 'Refractive amblyopia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lacrimal duct probing</strong> – Lacrimal duct probing is the first-line intervention for young infants with symptoms of congenital NLD obstruction that persist beyond the age of six months (<a class="graphic graphic_picture graphicRef76279" href="/d/graphic/76279.html" rel="external">picture 6</a>). The procedure is performed by an ophthalmologist in the office or the operating room, depending upon the experience and preference of the ophthalmologist and the age and size of the child (children ≥12 months old or weighing ≥9 kg usually require general anesthesia). In the office setting, the probing procedure usually takes only two to three minutes if the child's anatomy is normal [<a href="#rid1">1</a>]. (See <a class="local">'Lacrimal duct probing'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing</strong> – The optimal timing of intervention for infants with congenital NLD obstruction is an area of controversy. Many ophthalmologists perform early probing in the office if symptoms have not resolved by the age of 6 to 10 months. However, a reasonable alternative is to wait until the infant is 12 months since many patients will have spontaneous resolution by this age. NLD obstructions that persist beyond the age of 12 months are unlikely to resolve spontaneously [<a href="#rid4">4</a>]. Parental preferences play an important role in the decision to perform early probing versus deferring intervention.</p><p></p><p class="bulletIndent1">The <strong>advantages of early probing</strong> (ie, at age 6 to 10 months) compared with deferring the procedure until the child is ≥12 months of age are as follows [<a href="#rid1">1,2,8,13</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The procedure can usually be performed in the office without general anesthesia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>It results in earlier resolution of symptoms. Thus, early probing may be particularly helpful for infants with very bothersome symptoms.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The risk of lacrimal duct scarring may be lower.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The risk of infection may be lower (though is it fairly low even without intervention).</p><p></p><p class="bulletIndent1">The <strong>advantages of deferring intervention</strong> (ie, waiting until the infant is ≥12 months old) are as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>It allows more time for spontaneous resolution and thus avoids the need for intervention in some infants. (See <a class="local">'Natural history'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>It allows the ophthalmologist to perform a more definitive procedure. This is because most children require general anesthesia at this age in order to undergo a lacrimal duct procedure. The need for general anesthesia allows the ophthalmologist to perform a more complex procedure (eg, balloon dacryoplasty and/or NLD intubation) rather than a simple probing procedure. Both balloon dacryoplasty and NLD intubation generally have a higher success rate than simple probing, but they cannot be performed in the office setting without general anesthesia. These procedures are discussed in greater detail below. (See <a class="local">'Balloon dacryocystoplasty'</a> below and <a class="local">'Nasolacrimal duct intubation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – The efficacy of NLD probing for treatment of congenital NLD obstruction is supported by two small randomized trials, case series, and clinical experience [<a href="#rid14">14-19</a>]. NLD probing is successful in relieving the obstruction in approximately 75 to 90 percent of cases [<a href="#rid14">14-17</a>].</p><p></p><p class="bulletIndent1">Studies are inconsistent regarding the relationship between the age at which probing is performed and the success rate [<a href="#rid3">3,6,15-18</a>]. In a large multicenter prospective study, no association was observed between age and success rate in children &lt;3 years old [<a href="#rid18">18</a>]. The probability of success was slightly lower when the procedure was performed in the office setting rather than a surgical facility (72 versus 80 percent). In another large retrospective study, success was more likely in patients who underwent initial probing at age &lt;15 months compared with older age [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1">Outcomes with early versus deferred probing were evaluated in a multicenter randomized controlled trial of 163 infants with congenital NLD obstruction with unresolved symptoms at 6 to 10 months of age [<a href="#rid8">8</a>]. Patients were randomly assigned to immediate office-based probing (n = 82) or six months of nonsurgical management (n = 81) followed by surgical intervention (under general anesthesia) for those with persistent symptoms. Among patients in the deferred surgery group, 66 percent had resolution of symptoms without surgery and 27 percent underwent surgery (four of whom had early surgery because of worsening symptoms, parent request, or development of cellulitis within the observation period). Among patients in the early probing group, 9 percent required reoperation under general anesthesia for persistent NLD obstruction after the initial procedure. At age 18 months, more patients in the early probing group had complete resolution of symptoms compared with the deferred intervention group (92 versus 82 percent; absolute difference 10 percent, 95% CI -1 to 21 percent). The early probing group experienced three fewer months of symptoms (95% CI 1.8-4 fewer months).</p><p></p><p class="bulletIndent1">Cost effectiveness studies have reached different conclusions about the relative costs of the two approaches, with some estimating lower costs for patients treated with early office probing, while other estimates yielded comparable costs with both approaches [<a href="#rid8">8,20,21</a>].</p><p></p><p class="headingAnchor" id="H12"><span class="h3">Treatment failure</span><span class="headingEndMark"> — </span>Initial NLD probing is unsuccessful in 10 to 25 percent of cases [<a href="#rid14">14,18</a>]. Options for further management of these infants include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Repeat probing procedure</strong> – If the first probing procedure was uncomplicated and the infant is &lt;12 months or &lt;9 kg, repeat office probing may be attempted. Reported success rates for repeat probing range from 50 to 60 percent [<a href="#rid19">19</a>]. (See <a class="local">'Lacrimal duct probing'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternative procedures</strong> – Procedures that are used for second-line treatment after unsuccessful probing include NLD intubation and balloon dilation. These procedures can also be used for primary treatment in patients whose first procedure is performed under general anesthesia and for those with a high likelihood of treatment failure with probing (those who have tight obstructions or anatomic abnormalities such as craniosynostosis or other craniofacial abnormalities). Both procedures require general anesthesia. (See <a class="local">'Nasolacrimal duct intubation'</a> below and <a class="local">'Balloon dacryocystoplasty'</a> below.)</p><p></p><p class="bulletIndent1">Dacryocystorhinostomy and conjunctivodacryocystorhinostomy are more complex procedures that are reserved for patients with abnormal anatomy such as bony obstruction or punctal/canalicular aplasia and/or those with symptoms refractory to more standard treatments. (See <a class="local">'Dacryocystorhinostomy'</a> below and <a class="local">'Conjunctivodacryocystorhinostomy'</a> below.)</p><p></p><p class="headingAnchor" id="H2952889403"><span class="h2">Specific procedures</span></p><p class="headingAnchor" id="H3974309679"><span class="h3">Lacrimal duct probing</span><span class="headingEndMark"> — </span>Lacrimal duct probing is the first-line procedure for young infants with symptoms of congenital NLD obstruction. The procedure can be performed in the office with local anesthesia or in the operating room under general anesthesia. Children ≥12 months usually require general anesthesia.</p><p>The procedure is performed by inserting a small blunt probe or irrigation cannula into the punctum and advancing it through the lacrimal drainage system until it abuts the obstruction (<a class="graphic graphic_picture graphicRef76279" href="/d/graphic/76279.html" rel="external">picture 6</a>). The probe is then pushed gently through the obstruction into the nose. Irrigation with fluorescein-stained <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> may be performed to ensure patency. NLD probing is successful in relieving the obstruction in approximately 75 to 90 percent of cases [<a href="#rid14">14-17</a>].</p><p class="headingAnchor" id="H515737456"><span class="h3">Nasolacrimal duct intubation</span><span class="headingEndMark"> — </span>NLD intubation involves probing the NLD and placing a silicone stent within it. Stents usually are removed in the office after two to six months. NLD intubation is commonly used for patients who fail initial NLD probing. It is also used for primary treatment in infants and children whose first procedure is performed under general anesthesia. Reported success rates with this procedure are 90 to 96 percent when used for primary treatment and 84 percent when performed after failed probing [<a href="#rid22">22-24</a>]. It is not known whether early stent removal results in lower success rates.</p><p class="headingAnchor" id="H3777347893"><span class="h3">Balloon dacryocystoplasty</span><span class="headingEndMark"> — </span>Balloon dilation of the NLD can be used to increase the likelihood of successful treatment. Reported success rates of this procedure are 82 percent when used for primary treatment and 77 percent when performed after failed probing [<a href="#rid22">22,25</a>].</p><p class="headingAnchor" id="H4066126305"><span class="h3">Dacryocystorhinostomy</span><span class="headingEndMark"> — </span>Dacryocystorhinostomy is reserved for patients with bony obstruction and/or those with symptoms refractory to more standard treatments. The procedure involves the creation of a window between the lacrimal sac and nasal cavity. This procedure preserves the active drainage mechanism.</p><p class="headingAnchor" id="H1607846676"><span class="h3">Conjunctivodacryocystorhinostomy</span><span class="headingEndMark"> — </span>Conjunctivodacryocystorhinostomy is reserved for patients with significant anatomic abnormalities proximal to the lacrimal sac (eg, punctal or canalicular aplasia) that cannot be addressed with the procedures described above. In this procedure, a Pyrex glass tube is placed between the caruncle and the nasal cavity. This procedure relies solely on gravity for drainage.</p><p class="headingAnchor" id="H13"><span class="h1">DACRYOCYSTOCELE</span></p><p class="headingAnchor" id="H772425231"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>Dacryocystoceles usually are noted at or shortly after birth. A bluish swelling of the skin overlying the lacrimal sac and superior displacement of the medial canthal tendon are the typical findings (<a class="graphic graphic_picture graphicRef62273" href="/d/graphic/62273.html" rel="external">picture 1</a>). The diagnosis is made clinically, and further work-up generally is not necessary, although neuroimaging (<a class="graphic graphic_diagnosticimage graphicRef50760" href="/d/graphic/50760.html" rel="external">image 1</a>) can confirm the diagnosis.</p><p class="headingAnchor" id="H772425294"><span class="h2">Complications</span><span class="headingEndMark"> — </span>Children with dacryocystoceles should be promptly referred to an ophthalmologist. They may require early intervention because of two potential complications: infection and breathing difficulties from nasal obstruction [<a href="#rid26">26,27</a>].</p><p class="headingAnchor" id="H935169726"><span class="h3">Infection</span><span class="headingEndMark"> — </span>If left untreated, dacryocystoceles may become infected (<a class="graphic graphic_picture graphicRef65777" href="/d/graphic/65777.html" rel="external">picture 5</a>) [<a href="#rid26">26,28,29</a>]. Acute dacryocystitis requires prompt treatment with systemic antibiotics to prevent the development of secondary preseptal or orbital cellulitis, sepsis, meningitis, or brain abscess. (See <a class="local">'Management of acute dacryocystitis'</a> below.)</p><p>The risk of acute dacryocystitis is considerably higher in infants with dacryocystoceles compared with those with simple nasolacrimal duct (NLD) obstruction because of the greater degree of tear pool stasis. Clinical signs include erythema, swelling, tenderness, purulent discharge, and fever (<a class="graphic graphic_picture graphicRef65777" href="/d/graphic/65777.html" rel="external">picture 5</a>). Subtle early symptoms of infection include mild erythema over the lacrimal sac, poor feeding, or altered behavior.</p><p class="headingAnchor" id="H1710533834"><span class="h3">Breathing difficulties</span><span class="headingEndMark"> — </span>Distension of the mucosal lining of the NLD from entrapment of tears can create mucoceles that extend into the nose and cause obstruction. Because infants are obligate nose breathers, nasal obstruction from mucoceles can cause respiratory distress [<a href="#rid30">30-33</a>].</p><p class="headingAnchor" id="H943291"><span class="h2">Management</span><span class="headingEndMark"> — </span>Children with dacryocystoceles should be seen promptly by an ophthalmologist.</p><p class="headingAnchor" id="H565999051"><span class="h3">Decompression</span><span class="headingEndMark"> — </span>Decompression of a dacryocystocele into the fornices can usually be achieved with digital massage and/or probing of the common canaliculus in the office setting. Some ophthalmologists may observe for a short period of time to look for spontaneous resolution. Probing of the NLD, if required, is performed in a similar manner as in older infants with NLD obstruction. (See <a class="local">'Lacrimal duct probing'</a> above.)</p><p>In addition, if an intranasal mucocele is present (diagnosed by examining the nasal cavity using a headlight and nasal speculum), it must be opened to prevent recurrence of the obstruction. The intranasal component can be opened in the office, but more complex cases are best managed in the operating room under general anesthesia, sometimes with the aid of a nasal endoscope. Marsupialization is required.</p><p class="headingAnchor" id="H2629583969"><span class="h3">Management of acute dacryocystitis</span><span class="headingEndMark"> — </span>Acute dacryocystitis (<a class="graphic graphic_picture graphicRef65777" href="/d/graphic/65777.html" rel="external">picture 5</a>) requires prompt treatment with systemic antibiotics to prevent the development of secondary complications (eg, preseptal or orbital cellulitis, sepsis, meningitis, or brain abscess). (See  <a class="medical medical_review" href="/d/html/16650.html" rel="external">"Preseptal cellulitis"</a> and  <a class="medical medical_review" href="/d/html/3414.html" rel="external">"Orbital cellulitis"</a> and  <a class="medical medical_review" href="/d/html/5968.html" rel="external">"Bacterial meningitis in children older than one month: Clinical features and diagnosis"</a>.)</p><p>Infants and children with acute dacryocystitis should be managed in consultation with an ophthalmologist. If NLD probing is to be performed, systemic antibiotics should be administered preoperatively [<a href="#rid34">34</a>]. Blood cultures and cultures of material obtained during drainage should be sent for culture to guide definitive antimicrobial therapy [<a href="#rid35">35</a>]. The most common causative organisms include alpha-hemolytic streptococci, <em>Staphylococcus epidermidis</em>, and <em>Staphylococcus aureus</em> [<a href="#rid28">28</a>].</p><p>Empiric systemic antibiotic therapy should be provided to patients with suspected acute dacryocystitis pending culture results. The choice of antibiotic depends upon the severity of the infection. For severe infections, empiric therapy typically consists of intravenous <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> plus an extended-spectrum cephalosporin to provide broad coverage. Mild infections can be treated with oral <a class="drug drug_pediatric" data-topicid="13167" href="/d/drug information/13167.html" rel="external">clindamycin</a>.</p><p>Empiric antimicrobial therapy should be altered as warranted when culture results are available. The duration of antimicrobial therapy varies depending on clinical response but is usually 7 to 10 days.</p><p class="headingAnchor" id="H25519910"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword[s] of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/16717.html" rel="external">"Patient education: Blocked tear ducts in babies (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital nasolacrimal duct (NLD) obstruction</strong> – Simple congenital NLD obstruction (dacryostenosis) occurs in approximately 6 percent of newborns and is the most common cause of persistent tearing and eye discharge in infants and young children. Spontaneous resolution occurs in approximately 80 to 90 percent of infants with congenital NLD obstruction. (See <a class="local">'Epidemiology'</a> above and <a class="local">'Natural history'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical features</strong> – Infants with congenital NLD obstruction present with a history of chronic or intermittent tearing and debris on the eyelashes ("mattering") (<a class="graphic graphic_picture graphicRef62518" href="/d/graphic/62518.html" rel="external">picture 3</a> and <a class="graphic graphic_picture graphicRef52654" href="/d/graphic/52654.html" rel="external">picture 2</a>). On physical examination, there is often an increase in the size of the tear meniscus. Palpation of the lacrimal sac may cause reflux of tears and/or mucoid discharge onto the eye through the puncta. Conjunctival erythema is not typical. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diagnosis</strong> – The diagnosis of congenital NLD obstruction is typically made by history and physical examination alone. If symptoms are intermittent and signs of abnormal tearing or "mattering" are not present at the time of examination, the dye disappearance test can be performed to help confirm the diagnosis. (See <a class="local">'Evaluation and diagnosis'</a> above.)</p><p></p><p class="bulletIndent2">The differential diagnosis includes other causes of persistent tearing, which are summarized in the table (<a class="graphic graphic_table graphicRef63904" href="/d/graphic/63904.html" rel="external">table 1</a>). The absence of associated signs and symptoms distinguishes congenital NLD obstruction from other causes. (See <a class="local">'Differential diagnosis'</a> above and  <a class="medical medical_review" href="/d/html/6262.html" rel="external">"Approach to the child with persistent tearing", section on 'Etiology of persistent tearing'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Referral</strong> – Most infants with congenital NLD obstruction can be managed by the primary care practitioner. Referral to an ophthalmologist is warranted if any of the following are present (see <a class="local">'Indications for referral'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Uncertain diagnosis, particularly if there is concern for infantile glaucoma (see  <a class="medical medical_review" href="/d/html/6273.html" rel="external">"Primary infantile glaucoma"</a>)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Symptoms of NLD obstruction that persist beyond the age of six to seven months (see <a class="local">'Epidemiology'</a> above)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Signs and symptoms of acute dacryocystitis (see <a class="local">'Infection'</a> above)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Signs of anisometropia or amblyopia (see  <a class="medical medical_review" href="/d/html/6260.html" rel="external">"Refractive errors in children"</a> and  <a class="medical medical_review" href="/d/html/6255.html" rel="external">"Amblyopia in children: Classification, screening, and evaluation"</a>)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Clinical findings suggesting dacryocystocele (<a class="graphic graphic_picture graphicRef62273" href="/d/graphic/62273.html" rel="external">picture 1</a>) (see <a class="local">'Dacryocystocele'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial management</strong> – Initial management of congenital NLD obstruction is usually nonsurgical and consists of lacrimal sac massage (<a class="graphic graphic_figure graphicRef101426" href="/d/graphic/101426.html" rel="external">figure 3</a>) and observation (<a class="graphic graphic_algorithm graphicRef101554" href="/d/graphic/101554.html" rel="external">algorithm 1</a>). (See <a class="local">'Lacrimal sac massage'</a> above.)</p><p></p><p class="bulletIndent2">Mucopurulent eye discharge occurs commonly in infants with NLD obstruction and, in the absence of other signs of infection, suggests bacterial overgrowth in the stagnant tear pool of the lacrimal sac. This can usually be managed with nonpharmacological measures such as eye washes and nasolacrimal sac compression. If these measures are not successful and copious mucopurulent discharge is present throughout the day, we suggest treatment with topical antibiotics (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Commonly used agents include <a class="drug drug_pediatric" data-topicid="12845" href="/d/drug information/12845.html" rel="external">tobramycin</a> sulfate 0.3%, polymyxin/<a class="drug drug_pediatric" data-topicid="12865" href="/d/drug information/12865.html" rel="external">trimethoprim</a>, <a class="drug drug_pediatric" data-topicid="13332" href="/d/drug information/13332.html" rel="external">gentamicin</a>, or <a class="drug drug_pediatric" data-topicid="114796" href="/d/drug information/114796.html" rel="external">moxifloxacin</a> 0.5%, one drop up to four times per day for three to five days. (See <a class="local">'Treatment of bacterial overgrowth'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Persistent symptoms</strong> – For infants with symptoms of congenital NLD obstruction that persist beyond age 6 to 10 months, we suggest office-based lacrimal duct probing (<a class="graphic graphic_picture graphicRef76279" href="/d/graphic/76279.html" rel="external">picture 6</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). The procedure is performed by the ophthalmologist in the office with local anesthesia. Deferring intervention until the child is older (ie, &gt;12 months) is a reasonable alternative since NLD obstruction resolves spontaneously in many patients; however, general anesthesia is usually needed when the procedure is performed at this age. When the procedure is performed under general anesthesia, we suggest NLD intubation rather than simple probing (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Persistent nasolacrimal duct obstruction beyond age 6 to 7 months'</a> above.)</p><p></p><p class="bulletIndent2">If the initial NLD probing procedure is unsuccessful, options for further management include a second probing procedure or an alternative procedure (eg, NLD intubation or balloon dacryocystoplasty). (See <a class="local">'Treatment failure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital dacryocystocele</strong> – Congenital dacryocystoceles (or NLD cysts (<a class="graphic graphic_picture graphicRef62273" href="/d/graphic/62273.html" rel="external">picture 1</a>)) are less common than simple NLD obstruction. They are associated with potentially serious complications and thus require timely referral to an ophthalmologist. (See <a class="local">'Dacryocystocele'</a> above.)</p><p></p><p class="bulletIndent1">Dacryocystoceles usually are noted at or shortly after birth. They appear as a bluish swelling of the skin overlying the lacrimal sac and superior displacement of the medial canthal tendon (<a class="graphic graphic_picture graphicRef62273" href="/d/graphic/62273.html" rel="external">picture 1</a>). (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1">Infants with dacryocystoceles should be seen urgently by an ophthalmologist because of the risk of infection (acute dacryocystitis (<a class="graphic graphic_picture graphicRef65777" href="/d/graphic/65777.html" rel="external">picture 5</a>) and other secondary infections) and/or respiratory difficulties from nasal obstruction. (See <a class="local">'Complications'</a> above and <a class="local">'Management'</a> above.)</p><p></p><p class="headingAnchor" id="H3995653949"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Michael Cassidy, COT, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Örge FH, Boente CS. The lacrimal system. Pediatr Clin North Am 2014; 61:529.</a></li><li><a class="nounderline abstract_t">Olitsky SE. Update on congenital nasolacrimal duct obstruction. Int Ophthalmol Clin 2014; 54:1.</a></li><li><a class="nounderline abstract_t">Maini R, MacEwen CJ, Young JD. The natural history of epiphora in childhood. Eye (Lond) 1998; 12 ( Pt 4):669.</a></li><li><a class="nounderline abstract_t">MacEwen CJ, Young JD. Epiphora during the first year of life. Eye (Lond) 1991; 5 ( Pt 5):596.</a></li><li><a class="nounderline abstract_t">Petersen RA, Robb RM. The natural course of congenital obstruction of the nasolacrimal duct. J Pediatr Ophthalmol Strabismus 1978; 15:246.</a></li><li><a class="nounderline abstract_t">Sathiamoorthi S, Frank RD, Mohney BG. Spontaneous Resolution and Timing of Intervention in Congenital Nasolacrimal Duct Obstruction. JAMA Ophthalmol 2018; 136:1281.</a></li><li><a class="nounderline abstract_t">Pediatric Eye Disease Investigator Group. Resolution of congenital nasolacrimal duct obstruction with nonsurgical management. Arch Ophthalmol 2012; 130:730.</a></li><li><a class="nounderline abstract_t">Pediatric Eye Disease Investigator Group. A randomized trial comparing the cost-effectiveness of 2 approaches for treating unilateral nasolacrimal duct obstruction. Arch Ophthalmol 2012; 130:1525.</a></li><li><a class="nounderline abstract_t">Piotrowski JT, Diehl NN, Mohney BG. Neonatal dacryostenosis as a risk factor for anisometropia. Arch Ophthalmol 2010; 128:1166.</a></li><li><a class="nounderline abstract_t">Kushner BJ. Congenital nasolacrimal system obstruction. Arch Ophthalmol 1982; 100:597.</a></li><li><a class="nounderline abstract_t">Qian Y, Traboulsi EI. Lacrimal sac compression, not massage. J Pediatr Ophthalmol Strabismus 2009; 46:252.</a></li><li><a class="nounderline abstract_t">Kuchar A, Lukas J, Steinkogler FJ. Bacteriology and antibiotic therapy in congenital nasolacrimal duct obstruction. Acta Ophthalmol Scand 2000; 78:694.</a></li><li><a class="nounderline abstract_t">Schnall BM. Pediatric nasolacrimal duct obstruction. Curr Opin Ophthalmol 2013; 24:421.</a></li><li><a class="nounderline abstract_t">Robb RM. Probing and irrigation for congenital nasolacrimal duct obstruction. Arch Ophthalmol 1986; 104:378.</a></li><li><a class="nounderline abstract_t">Katowitz JA, Welsh MG. Timing of initial probing and irrigation in congenital nasolacrimal duct obstruction. Ophthalmology 1987; 94:698.</a></li><li><a class="nounderline abstract_t">el-Mansoury J, Calhoun JH, Nelson LB, Harley RD. Results of late probing for congenital nasolacrimal duct obstruction. Ophthalmology 1986; 93:1052.</a></li><li><a class="nounderline abstract_t">Miller AM, Chandler DL, Repka MX, et al. Office probing for treatment of nasolacrimal duct obstruction in infants. J AAPOS 2014; 18:26.</a></li><li><a class="nounderline abstract_t">Pediatric Eye Disease Investigator Group, Repka MX, Chandler DL, et al. Primary treatment of nasolacrimal duct obstruction with probing in children younger than 4 years. Ophthalmology 2008; 115:577.</a></li><li><a class="nounderline abstract_t">Pediatric Eye Disease Investigator Group, Repka MX, Chandler DL, et al. Repeat probing for treatment of persistent nasolacrimal duct obstruction. J AAPOS 2009; 13:306.</a></li><li><a class="nounderline abstract_t">Frick KD, Hariharan L, Repka MX, et al. Cost-effectiveness of 2 approaches to managing nasolacrimal duct obstruction in infants: the importance of the spontaneous resolution rate. Arch Ophthalmol 2011; 129:603.</a></li><li><a class="nounderline abstract_t">Morrison DG, Binenbaum G, Chang MY, et al. Office- or Facility-Based Probing for Congenital Nasolacrimal Duct Obstruction: A Report by the American Academy of Ophthalmology. Ophthalmology 2021; 128:920.</a></li><li><a class="nounderline abstract_t">Repka MX, Chandler DL, Holmes JM, et al. Balloon catheter dilation and nasolacrimal duct intubation for treatment of nasolacrimal duct obstruction after failed probing. Arch Ophthalmol 2009; 127:633.</a></li><li><a class="nounderline abstract_t">Pediatric Eye Disease Investigator Group, Repka MX, Melia BM, et al. Primary treatment of nasolacrimal duct obstruction with nasolacrimal duct intubation in children younger than 4 years of age. J AAPOS 2008; 12:445.</a></li><li><a class="nounderline abstract_t">Engel JM, Hichie-Schmidt C, Khammar A, et al. Monocanalicular silastic intubation for the initial correction of congenital nasolacrimal duct obstruction. J AAPOS 2007; 11:183.</a></li><li><a class="nounderline abstract_t">Pediatric Eye Disease Investigator Group, Repka MX, Melia BM, et al. Primary treatment of nasolacrimal duct obstruction with balloon catheter dilation in children younger than 4 years of age. J AAPOS 2008; 12:451.</a></li><li><a class="nounderline abstract_t">Paysse EA, Coats DK, Bernstein JM, et al. Management and complications of congenital dacryocele with concurrent intranasal mucocele. J AAPOS 2000; 4:46.</a></li><li><a class="nounderline abstract_t">Wong RK, VanderVeen DK. Presentation and management of congenital dacryocystocele. Pediatrics 2008; 122:e1108.</a></li><li><a class="nounderline abstract_t">Campolattaro BN, Lueder GT, Tychsen L. Spectrum of pediatric dacryocystitis: medical and surgical management of 54 cases. J Pediatr Ophthalmol Strabismus 1997; 34:143.</a></li><li><a class="nounderline abstract_t">Schnall BM, Christian CJ. Conservative treatment of congenital dacryocele. J Pediatr Ophthalmol Strabismus 1996; 33:219.</a></li><li><a class="nounderline abstract_t">Edmond JC, Keech RV. Congenital nasolacrimal sac mucocele associated with respiratory distress. J Pediatr Ophthalmol Strabismus 1991; 28:287.</a></li><li><a class="nounderline abstract_t">Duval M, Alsabah BH, Carpineta L, Daniel SJ. Respiratory distress secondary to bilateral nasolacrimal duct mucoceles in a newborn. Otolaryngol Head Neck Surg 2007; 137:353.</a></li><li><a class="nounderline abstract_t">Yee SW, Seibert RW, Bower CM, Glasier CM. Congenital nasolacrimal duct mucocele: a cause of respiratory distress. Int J Pediatr Otorhinolaryngol 1994; 29:151.</a></li><li><a class="nounderline abstract_t">Leonard DS, O'Keefe M, Rowley H, Hughes JP. Neonatal respiratory distress secondary to bilateral intranasal dacryocystocoeles. Int J Pediatr Otorhinolaryngol 2008; 72:1873.</a></li><li><a class="nounderline abstract_t">Baskin DE, Reddy AK, Chu YI, Coats DK. The timing of antibiotic administration in the management of infant dacryocystitis. J AAPOS 2008; 12:456.</a></li><li class="breakAll">Hussein M, Miller AM, Steinkuller PG. Ocular infections. In: Feigin and Cherry’s Textbook of Pediatric Infectious Diseases, 7th ed, Cherry JD, Harrison GJ, Kaplan SL, et al (Eds), Elsevier Saunders, Philadelphia 2014. p.794.</li></ol></div><div id="topicVersionRevision">Topic 6274 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24852150" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The lacrimal system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24879099" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Update on congenital nasolacrimal duct obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9850262" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The natural history of epiphora in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1794426" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Epiphora during the first year of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/739359" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The natural course of congenital obstruction of the nasolacrimal duct.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30178001" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Spontaneous Resolution and Timing of Intervention in Congenital Nasolacrimal Duct Obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22801833" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Resolution of congenital nasolacrimal duct obstruction with nonsurgical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23229693" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A randomized trial comparing the cost-effectiveness of 2 approaches for treating unilateral nasolacrimal duct obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20837801" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Neonatal dacryostenosis as a risk factor for anisometropia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6896140" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Congenital nasolacrimal system obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19673055" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Lacrimal sac compression, not massage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11167236" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Bacteriology and antibiotic therapy in congenital nasolacrimal duct obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23846190" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pediatric nasolacrimal duct obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3954637" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Probing and irrigation for congenital nasolacrimal duct obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3627719" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Timing of initial probing and irrigation in congenital nasolacrimal duct obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3763154" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Results of late probing for congenital nasolacrimal duct obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24568978" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Office probing for treatment of nasolacrimal duct obstruction in infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17996306" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Primary treatment of nasolacrimal duct obstruction with probing in children younger than 4 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19541274" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Repeat probing for treatment of persistent nasolacrimal duct obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21555614" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cost-effectiveness of 2 approaches to managing nasolacrimal duct obstruction in infants: the importance of the spontaneous resolution rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33358412" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Office- or Facility-Based Probing for Congenital Nasolacrimal Duct Obstruction: A Report by the American Academy of Ophthalmology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19433712" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Balloon catheter dilation and nasolacrimal duct intubation for treatment of nasolacrimal duct obstruction after failed probing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18595756" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Primary treatment of nasolacrimal duct obstruction with nasolacrimal duct intubation in children younger than 4 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17307001" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Monocanalicular silastic intubation for the initial correction of congenital nasolacrimal duct obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18929305" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Primary treatment of nasolacrimal duct obstruction with balloon catheter dilation in children younger than 4 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10675871" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Management and complications of congenital dacryocele with concurrent intranasal mucocele.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18955412" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Presentation and management of congenital dacryocystocele.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9168418" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Spectrum of pediatric dacryocystitis: medical and surgical management of 54 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8880613" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Conservative treatment of congenital dacryocele.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1955967" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Congenital nasolacrimal sac mucocele associated with respiratory distress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17666273" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Respiratory distress secondary to bilateral nasolacrimal duct mucoceles in a newborn.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8056498" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Congenital nasolacrimal duct mucocele: a cause of respiratory distress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18990457" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Neonatal respiratory distress secondary to bilateral intranasal dacryocystocoeles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18595757" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The timing of antibiotic administration in the management of infant dacryocystitis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
